Capricor Therapeutics

Executive Summary

On March 10, 2026, Capricor Therapeutics announced that the FDA has lifted its Complete Response Letter (CRL) and resumed review of the Biologics License Application (BLA) for Deramiocel. The agency assigned a new PDUFA target action date of August 22, 2026—a pivotal moment after months of regulatory uncertainty.

This reversal comes just three months after Capricor announced positive topline results from the Phase 3 HOPE-3 trial in December 2025, which met its primary endpoint (54% slowing of upper limb function decline, p=0.03) and achieved statistical significance on the key cardiac secondary endpoint (91% slowing of left ventricular ejection fraction decline, p=0.04). The company’s stock surged approximately 17% on the news.

This report traces the journey of Deramiocel: from years of Phase 2 promise, through an unexpected CRL in July 2025, to the December 2025 Phase 3 success, and finally to this March 2026 regulatory reprieve. We analyze the science, the regulatory drama, financial implications, and the clinical case for Deramiocel as a potential first-in-class therapy addressing both skeletal and cardiac manifestations of Duchenne muscular dystrophy.

About Duchenne Muscular Dystrophy (DMD)

Duchenne muscular dystrophy is a severe, X-linked genetic disorder affecting approximately 15,000 individuals in the United States, primarily boys and young men. The disease results from mutations in the DMD gene, leading to the absence of functional dystrophin—a critical structural protein in muscle cells.

The hallmark of DMD is progressive muscle degeneration affecting skeletal, respiratory, and cardiac muscles. While the loss of lower limb function (ambulatory decline) is characteristic in early disease, cardiomyopathy emerges as the leading cause of mortality as patients progress. By adolescence and early adulthood, most DMD patients develop significant cardiac dysfunction, leading to heart failure and premature death.

Current treatment options remain limited. Corticosteroids slow skeletal muscle decline but do not address cardiac pathology. Recent gene therapy approvals (e.g., Sarepta’s Elevidys) have offered hope for selective populations, but no approved therapy broadly addresses both the skeletal and cardiac aspects of DMD. This dual unmet need is where Deramiocel aims to intervene.

About Deramiocel (CAP-1002)

Deramiocel is an allogeneic cell therapy consisting of cardiosphere-derived cells (CDCs)—rare populations of cardiac progenitor cells isolated from donor hearts. These cells have been engineered to exert potent immunomodulatory and anti-fibrotic effects in preserving muscle function.

Mechanism of Action

Rather than replacing damaged muscle directly, CDCs work through paracrine signaling. They secrete extracellular vesicles (exosomes) that target macrophages and reprogram them from a pro-inflammatory phenotype to a healing, anti-fibrotic phenotype. This immune modulation:

• Reduces cardiac fibrosis and preserves left ventricular function
• Attenuates skeletal muscle inflammation and slows disease progression
• Promotes a tissue-protective microenvironment

The therapy is dosed as 150 million cells per intravenous infusion, administered quarterly for 12 months (total of 4 doses).

Regulatory Status & Designations

• Orphan Drug Designation (ODD): FDA and EMA
• Regenerative Medicine Advanced Therapy (RMAT): FDA
• Advanced Therapy Medicinal Product (ATMP): EMA
• Rare Pediatric Disease Designation (RPDD): FDA (qualifies for Priority Review Voucher upon approval)

⏳ Timeline: The Road to August 2026 PDUFA

• March 2025 Priority Review Granted – FDA accepts BLA for Deramiocel based on HOPE-2 Phase 2 data. Initial PDUFA: August 31, 2025.
• June 2025 FDA Cancels Advisory Committee Meeting – Without advance notice to Capricor. Signals underlying regulatory concerns.
• July 11, 2025 Complete Response Letter (CRL) Issued – FDA cites insufficient clinical evidence and CMC issues. Shock to the market; stock falls. FDA offers Type A meeting.
• July–September 2025 Type A Meeting & FDA Alignment – FDA agrees that Phase 3 HOPE-3 data “should be sufficient to support regulatory approval” if positive. Clear regulatory pathway established.
• June 22, 2022 – December 2025 HOPE-3 Phase 3 Trial Completion – Randomized, double-blind, placebo-controlled trial (n=106) across 20 U.S. sites. Ambulatory and non-ambulatory DMD boys. 4 doses over 12 months.
• December 3, 2025 HOPE-3 Topline Results: SUCCESS – Primary endpoint (PUL v2.0): 54% slowing of upper limb decline (p=0.029). Key secondary (LVEF): 91% slowing of cardiac decline (p=0.041). Stock rises 282% in one week.
• February 2026 HOPE-3 Clinical Study Report Submitted – Full CSR filed with FDA to address CRL issues.
• March 10, 2026 CRL LIFTED, PDUFA ASSIGNED: August 22, 2026 – FDA resumes review. Class 2 resubmission. FDA states: “No potential review issues identified.” Stock up 10–17%.
• March 11, 2026 MDA Conference – Detailed HOPE-3 results presented in late-breaking oral session in Florida.
• August 22, 2026 PDUFA TARGET ACTION DATE – FDA decision expected (approval, CRL, or other action).

HOPE-3 Phase 3 Trial: The Data Deep Dive

Primary Efficacy Endpoint: Skeletal Muscle (Upper Limb Function)

The primary endpoint was change from baseline in Performance of Upper Limb (PUL v2.0) total score at 12 weeks—a validated assessment of upper limb strength and function in DMD patients.

Result: Deramiocel demonstrated a 54% slowing of upper limb function decline compared to placebo (p=0.029, statistically significant). In absolute terms, deramiocel-treated patients showed significantly better preservation of shoulder, elbow, and wrist function over 12 months.

Clinical Significance: A 54% slowing translates to meaningful preservation of independence in activities like feeding, hygiene, and upper body mobility—critical for quality of life in non-ambulatory DMD patients.

Key Secondary Efficacy Endpoint: Cardiac Function

The key secondary endpoint was change in left ventricular ejection fraction (LVEF%) over 12 months. LVEF is the gold standard measure of cardiac systolic function; declining LVEF is the hallmark of DMD cardiomyopathy and primary predictor of mortality.

Result: Deramiocel-treated patients showed a 91% slowing of cardiac function decline compared to placebo, as measured by LVEF preservation (p=0.041, statistically significant). At baseline, >75% of trial participants had clinical cardiomyopathy.

Clinical Significance: “The cardiac findings from HOPE-3 represent a significant advance in the management of Duchenne muscular dystrophy cardiomyopathy,” per Jonathan Soslow, MD, MSCI, Vanderbilt University Medical Center.

Safety & Other Endpoints

Deramiocel maintained a favorable safety profile consistent with prior trials. Statistical significance was achieved in all Type I error–controlled secondary endpoints, including hand-to-mouth function, biomarkers (CK-MB), and quality of life assessments.

Regulatory Strategy: How Capricor Overcame the CRL

The CRL Controversy

The July 2025 CRL was controversial. Capricor had received Priority Review, completed a successful mid-cycle review, passed a pre-licensure FDA inspection, and followed FDA guidance throughout. Yet the FDA cited “insufficient substantial evidence of efficacy” based on HOPE-2—a Phase 2 trial of only 26 patients.

Capricor disputed this, arguing that the primary endpoint was met using the correct statistical test. However, regulatory disputes are not easily won; the FDA holds the authority to determine what constitutes “adequate” evidence.

Type A Meeting Breakthrough

The Type A meeting in summer 2025 was the critical turning point. The FDA agreed that HOPE-3 should serve as the “additional study” to resolve the efficacy questions raised in the CRL. Key alignment points:

• HOPE-3 data can be submitted within the current BLA (no new application needed)
• PUL v2.0 remains the primary efficacy endpoint
• LVEF is accepted as a key secondary endpoint for potential labeling
• FDA will exercise “regulatory flexibility” in reviewing HOPE-3 data

March 2026: CRL Lifted, Clear Path

Upon receipt of the HOPE-3 Clinical Study Report, the FDA lifted the CRL and resumed review. Notably, the agency stated: “The FDA has not identified any potential review issues in its response to the Company.” This is a strong signal that the regulatory pathway is now clear.

The classification as a “Class 2 resubmission” means Standard Review (not Priority Review), with a PDUFA clock of 10 months. The new PDUFA target date of August 22, 2026 is approximately 5.5 months away.

Financial Status & Partnership

As of September 30, 2025, Capricor held approximately $98.6 million in cash, cash equivalents, and marketable securities. Management stated this cash position is expected to support operations into Q4 2026.

Capricor has entered into an exclusive commercialization agreement with Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.) for Deramiocel in the United States and Japan, subject to regulatory approval.

If approved, Capricor is eligible to receive a Priority Review Voucher worth approximately $100 million+. The company could use the voucher on another program or sell it in the secondary market.

⚠️ Main Risk Factors

? Market Sentiment & Stock Performance

CAPR stock has been volatile but distinctly bullish post-HOPE-3:

• December 3, 2025 (HOPE-3 topline): Stock surged 282% in one week, from ~$7.39 (Sep 30, 2025) to highs above $29.
• March 10, 2026 (CRL lift): Stock up 10.89% to 17.21% in early trading.
• Technical setup: Trading well above 20-day, 50-day, and 200-day moving averages. Momentum strong.

Retail Sentiment: Mixed to cautiously bullish. HOPE-3 data and CRL lift are positive, but concerns exist about dilution (Dec 2025 capital raise), valuation, and small free float volatility.

Bottom Line: What It Means

Capricor’s March 10, 2026 announcement marks a critical inflection point for the company and the DMD community.

For Capricor: The CRL lift and new PDUFA date provide a clear path to a binary event in approximately 5.5 months. Regulatory risk has significantly de-risked, given the FDA’s statement that no new review issues have been identified. If approved, Deramiocel could generate meaningful revenue beginning Q4 2026 / Q1 2027, plus the $100 million+ PRV optionality.

For DMD Patients & Families: The positive HOPE-3 data and regulatory momentum offer hope for a new therapeutic option addressing both skeletal and cardiac disease aspects—an unmet need persisting for decades. Even a modest 54% slowing of upper limb decline and 91% slowing of cardiac decline could translate to years of preserved function and quality of life.

For Investors: CAPR is now a speculative-to-moderate-risk biotech play with a clear, near-term approval catalyst and compelling clinical data. Execution risk remains (manufacturing, commercial ramp, real-world efficacy), and the stock price has already appreciated significantly post-HOPE-3. Due diligence on financial runway, partner terms, and manufacturing capacity is essential.

The August 22, 2026 PDUFA date is circled on the calendar. All eyes will be on the FDA’s final decision.

? Primary Sources

• Capricor press release: CRL Lifted, PDUFA August 22, 2026 (Mar 10, 2026)
• Capricor press release: HOPE-3 Positive Topline Results (Dec 3, 2025)
• GlobeNewswire: HOPE-3 Results
• Capricor Regulatory Update: CRL Announcement (Jul 11, 2025)
• Capricor Type A Meeting Minutes & FDA Alignment (Sep 2025)
• ClinicalTrials.gov: HOPE-3 Trial (NCT05126758)
• SEC EDGAR: Capricor Therapeutics Filings (10-K, 10-Q)

? Related Merlintrader Articles